W hen diagnosed with diabetic macular edema (DME) in 2017, Sarah Castaneda, 41, thought she would lose her eyesight completely. At least, that’s what her doctor told her would happen if she didn’t ...

TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...

Diabetic macular edema treatment options include anti-vascular endothelial growth factor (anti-VEGF) injections and laser therapy, with patient-specific factors guiding the best approach. What are the ...

These injections can restore your eyesight and ward off vision loss. And they aren’t nearly as stressful as you might think. No one really looks forward to getting a shot — and when you’re living with ...

EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 ...

Resistant diabetic macular edema may necessitate transitioning from one intravitreal pharmacotherapy to another when the edema is persistent — a practice sometimes undertaken in clinical management.

Vabysmo now covered across all three approved indications in the province, providing patients with a comprehensively funded option for their needs "This expansion in coverage for people with RVO in ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated ...

Continuous administration of ranibizumab with a port delivery system provides an alternative to frequent intravitreal injections for diabetic macular edema and helps delay progression of ...

Please provide your email address to receive an email when new articles are posted on . One specialist highlighted cases in which systemic treatments, such as corticosteroids, are better. Another ...